Vimseltinib: First Approval

Arnold Lee

doi:10.1007/s40265-025-02191-z

2025-05-26

PRE

Arnold Lee *

DOI：10.1007/s40265-025-02191-z

原文链接

原文求助

摘要

En 中文

维姆色替尼（ROMVIMZA™）是一种口服的激酶抑制剂，靶向集落刺激因子1受体（CSF1R），由Deciphera Pharmaceuticals公司开发。由于CSF1R活性已被确认为腱鞘巨细胞瘤（TGCT）的促成因素，因此针对CSF1R的治疗方案已被研究。维姆色替尼于2025年2月在美国首次获批，用于治疗TGCT，并正在开发用于治疗慢性移植物抗宿主病。本文总结了维姆色替尼在开发过程中的关键里程碑，这些里程碑促成了其首次获批用于治疗成人症状性TGCT，特别是针对那些手术切除可能导致功能限制加重或严重病残的患者。

Keyword:

GIANT-CELL TUMOR

期刊

Drugs

IF:

14.4

论文数:

8.4K

被引数:

2.3W

机构

暂无机构信息

引用论文

Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial 更新后的vimelstinib在腱鞘巨细胞瘤（TGCT）患者中的疗效与安全性：MOTION III期试验的一年随访结果

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Gelderblom, H.; Bhadri, V. A.; Stacchiotti, S.; Bauer, S.; Wagner, A. J.; van de Sande, M.; Bernthal, N. M.; Pousa, A. Lopez; Razak, A. R. Abdul; Italiano, A.; Ahmed, M.; Le Cesne, A.; Tait, C.; Saunders, A.; Harrow, B.; Sharma, M. G.; Ruiz-Soto, R.; Sherman, M. L.; Blay, J-Y.; Tap, W. D.

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages

MOLECULAR CANCER THERAPEUTICS

IF5.5

2021-08-25

OAAI

Smith, Bryan D.; Kaufman, Michael D.; Wise, Scott C.; Ahn, Yu Mi; Caldwell, Timothy M.; Leary, Cynthia B.; Lu, Wei-Ping; Tan, Gege; Vogeti, Lakshminarayana; Vogeti, Subha; Wilky, Breelyn A.; Davis, Lara E.; Sharma, Maitreyi; Ruiz-Soto, Rodrigo; Flynn, Daniel L.

Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, doubleblind, placebo-controlled, phase 3 trial

LANCET

IF88.5

2024-06-01

PREAI

Gelderblom, Hans; Bhadri, Vivek; Stacchiotti, Silvia; Bauer, Sebastian; Wagner, Andrew J.; van de Sande, Michiel; Bernthal, Nicholas M.; Pousa, Antonio Lopez; Razak, Albiruni Abdul; Italiano, Antoine; Ahmed, Mahbubl; Le Cesne, Axel; Tinoco, Gabriel; Boye, Kjetil; Martin-Broto, Javier; Palmerini, Emanuela; Tafuto, Salvatore; Pratap, Sarah; Powers, Benjamin C.; Reichardt, Peter; Herraez, Antonio Casado; Rutkowski, Piotr; Tait, Christopher; Zarins, Fiona; Harrow, Brooke; Sharma, Maitreyi G.; Ruiz-Soto, Rodrigo; Sherman, Matthew L.; Blay, Jean-Yves; Tap, William D.

Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)

Bioorganic & Medicinal Chemistry Letters

IF0

2022-10-01

OAAI

Timothy M. Caldwell; Yu Mi Ahn; Stacie L. Bulfer; Cynthia B. Leary; Molly M. Hood; Wei-Ping Lu; Lakshminarayana Vogeti; Subha Vogeti; Michael D. Kaufman; Scott C. Wise; Bertrand Le Bourdonnec; Bryan D. Smith; Daniel L. Flynn

Updates on the Treatment of Tenosynovial Giant Cell Tumor 滑膜巨细胞瘤治疗的最新进展

Hematology/Oncology and Stem Cell Therapy

IF0

2023-05-23

OAAI

Abigail S. Chan; Vatsala Katiyar; Paul Dy; Vikas Singh

Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts

CANCER TREATMENT REVIEWS

IF10.5

2023-01-01

OAAI

Stacchiotti, Silvia; Duerr, Hans Roland; Schaefer, Inga-Marie; Woertler, Klaus; Haas, Rick; Trama, Annalisa; Caraceni, Augusto; Bajpai, Jyoti; Baldi, Giacomo Giulio; Bernthal, Nicholas; Blay, Jean-Yves; Boye, Kjetil; Broto, Javier-Martin; Chen, Wei-Wu Tom; Tos, Paolo Angelo Dei; Desai, Jayesh; Emhofer, Stephan; Eriksson, Mikael; Gronchi, Alessandro; Gelderblom, Hans; Hardes, Jendrik; Hartmann, Wolfgang; Healey, John; Italiano, Antoine; Jones, Robin L.; Kawai, Akira; Leithner, Andreas; Loong, Herbert; Mascard, Eric; Morosi, Carlo; Otten, Nadine; Palmerini, Emanuela; Patel, Shreyaskumar R.; Reichardt, Peter; Rubin, Brian; Rutkowski, Piotr; Sangalli, Claudia; Schuster, Kathrin; Seddon, Beatrice M.; Shkcodra, Morena; Staals, Eric L.; Tap, William; van de Rijn, Matt; van Langevelde, Kirsten; Vanhoenacker, Filip M. M.; Wagner, Andrew; Wiltink, Lisette; Stern, Sydney; Van de Sande, Michiel; Bauer, Sebastian

CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib CSF1R抑制剂在晚期实体瘤或腱鞘巨细胞瘤患者中的研究：一项Vimseltinib的I期临床研究

Clinical Cancer Research

IF0

2024-07-12

OAAI

Hans Gelderblom; Albiruni A. Razak; Matthew H. Taylor; Todd M. Bauer; Breelyn Wilky; Javier Martin-Broto; Alejandro F. Gonzalez; Piotr Rutkowski; Bartlomiej Szostakowski; Thierry Alcindor; Ramy Saleh; Sofia Genta; Silvia Stacchiotti; Michiel van de Sande; Andrew J. Wagner; Nicholas Bernthal; Lara E. Davis; Jacqueline Vuky; Christopher Tait; Bahar Matin; Supraja Narasimhan; Maitreyi G. Sharma; Rodrigo Ruiz-Soto; Matthew L. Sherman; William D. Tap

没有更多内容